Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis

BACKGROUND: For patients with rheumatoid arthritis (RA) who discontinued initial treatment with tumor necrosis factor inhibitor (TNFi), 2 approaches are commonly used: cycling to another TNFi or switching to a drug with another mechanism of action. Currently, there is no consensus on which approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Karpes Matusevich, Aliza R, Lal, Lincy S, Chan, Wenyaw, Swint, J Michael, Cantor, Scott B, Suarez-Almazor, Maria E, Lopez-Olivo, Maria A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391179/
https://www.ncbi.nlm.nih.gov/pubmed/33377443
http://dx.doi.org/10.18553/jmcp.2021.27.1.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391179/
https://www.ncbi.nlm.nih.gov/pubmed/33377443
http://dx.doi.org/10.18553/jmcp.2021.27.1.073

Ejemplares similares